FrancophonIA/ELRC3.0 huggingface dataset:
English: • patients who have recently had a myocardial infarction (heart attack).
Estonian: • kellel on hiljuti olnud südameinfarkt.
English: Other information about Clopidogrel Acino
Estonian: Muu teave Clopidogrel Acino kohta
English: This means that Clopidogrel Acino is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Estonian: See tähendab, et Clopidogrel Acino on sarnane võrdlusravimiga Plavix, millel juba on Euroopa Liidus müügiluba.
English: Because Clopidogrel Acino is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as those of the reference medicine.
Estonian: Et Clopidogrel Acino on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: EPAR summary for the public clopidogrel
Estonian: Kokkuvõte üldsusele
English: Clopidogrel Acino can be started between a few days and 35 days after the attack;
Estonian: Clopidogrel Acino manustamist tohib alustada mõne kuni 35 päeva jooksul pärast infarkti;
English: The CHMP concluded that, in accordance with EU requirements, Clopidogrel Acino has been shown to have comparable quality and to be bioequivalent to Plavix.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Clopidogrel Acino võrdväärne kvaliteet ja bioekvivalentsus ravimiga Plavix.
English: In acute coronary syndrome, Clopidogrel Acino is used together with aspirin and treatment generally starts with a loading dose of four 75 mg tablets.
Estonian: Ägeda koronaarsündroomi korral algab ravi üldiselt küllastusannusega, mille korral võetakse neli 75 mg tabletti.
English: Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel Acino kasulikkus sellega kaasnevad riskid.
English: Clopidogrel Acino is a medicine that contains the active substance clopidogrel.
Estonian: Clopidogrel Acino on ravim, mis sisaldab toimeainena klopidogreeli.
English: Clopidogrel Acino is a ‘generic medicine'.
Estonian: Clopidogrel Acino on geneeriline ravim.
English: Because Clopidogrel Acino is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Estonian: Et Clopidogrel Acino on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Clopidogrel Acino bioekvivalentsust võrdlusravimiga Plavix.
English: What is Clopidogrel Acino?
Estonian: Mis on Clopidogrel Acino?
English: Why has Clopidogrel Acino been approved?
Estonian: Miks Clopidogrel Acino heaks kiideti?
English: • patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Estonian: • kellel on hiljuti olnud isheemiline insult (peaaju teatud osa verevarustushäiretest tingitud insult).
English: Clopidogrel Acino is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Estonian: Clopidogrel Acinot kasutatakse trombidest (soonesisestest verehüüvetest) põhjustatud probleemide ennetamiseks järgmistel täiskasvanutel:
English: How has Clopidogrel Acino been studied?
Estonian: Kuidas Clopidogrel Acinot uuriti?
English: How does Clopidogrel Acino work?
Estonian: Kuidas Clopidogrel Acino toimib?
English: How is Clopidogrel Acino used?
Estonian: Kuidas Clopidogrel Acinot kasutatakse?
English: What is Clopidogrel Acino used for?
Estonian: Milleks Clopidogrel Acinot kasutatakse?
English: • patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
Estonian: • kellel on äge koronaarsündroom, mille korral tuleb Clopidogrel Acinot manustada koos aspiriiniga (samuti antikoagulant).
English: What are the benefits and risks of Clopidogrel Acino?
Estonian: Milles seisneb Clopidogrel Acino kasulikkus ja mis riskid ravimiga kaasnevad?
English: The active substance in Clopidogrel Acino, clopidogrel, is an inhibitor of platelet aggregation.
Estonian: Clopidogrel Acino toimeaine klopidogreel on trombotsüütide agregatsiooni inhibiitor, mis aitab ennetada trombide (soonesiseste verehüüvete) tekkimist.
English: It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or have had a ‘non-Q-wave' myocardial infarction.
Estonian: Ravim on näidustatud patsientidele, kellel on vähemalt üks vaskulaarhäirete, näiteks südameinfarkti või insuldi riskitegur, kes ei saa võtta K-vitamiini antagoniste (samuti vere hüübimist takistavad ravimid) ja kellel on väiksem verejooksu risk.
English: Cholib fenofibrate / simvastatin
Estonian: Cholib fenofibraat/simvastatiin
English: The full EPAR for Cholib can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Cholibi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Cholib
Estonian: Muu teave Cholibi kohta
English: A risk management plan has been developed to ensure that Cholib is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Cholibi võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Cholib?
Estonian: Mis meetmeid võetakse, et tagada Cholibi ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cholib on 26 August 2013.
Estonian: Euroopa Komisjon andis Cholibi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 26. augustil
English: What is Cholib and what is it used for?
Estonian: Mis on Cholib ja milleks seda kasutatakse?
English: The recommended dose is one tablet a day to be swallowed whole with a glass of water.
Estonian: Soovitatav annus on üks tablett päevas tervelt allaneelatuna koos klaasi veega.
English: Fenofibrate is a ‘PPARα agonist'.
Estonian: Fenofibraat on PPAR-α agonist.
English: The Committee therefore concluded that Cholib's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee järeldas seetõttu, et Cholibi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Cholib approved?
Estonian: Miks Cholib heaks kiideti?
English: It must also not be used in pregnant or breast-feeding women, in people known to have light-induced reactions to fibrates or ketoprofen, or those who have liver or gallbladder disease, pancreatitis, or moderately or severely reduced kidney function, or who have previously had muscle problems while taking statins or fibrates.
Estonian: Samuti ei tohi seda kasutada rasedad või imetavad naised, patsiendid, kellel esinevad valgusindutseeritud reaktsioonid fibraatidele või ketoprofeenile, maksa- või sapipõiehaiguste, pankreatiidi või mõõduka või raske neerutalitluse häirega patsiendid või need, kellel on varem esinenud statiinide või fibraatide võtmisel lihaseprobleeme.
English: The Committee also noted that the combination of fenofibrate and simvastatin is already being used in clinical practice.
Estonian: Inimravimite komitee märkis ka, et fenofibraadi ja simvastatiini kombinatsiooni juba kasutatakse kliinilises praktikas.
English: With regard to the safety of Cholib, the side effects reported in the studies were consistent with what is known about the two active substances and there were no major concerns.
Estonian: Cholibi ohutuse osas olid uuringutes teatatud kõrvanähud sarnased kahe toimeaine kohta teatatuga ja olulisi probleeme ei tuvastatud.
English: The cholesterol drawn out of the blood in this way is the ‘bad' cholesterol.
Estonian: Sel moel verest eemaldatud kolesterool on „halb” kolesterool.
English: It is not intended to provide practical advice on how to use Cholib.
Estonian: Hindamisaruandes ei anta Cholibi kasutamise praktilisi nõuandeid.
English: When these receptors are activated, the breakdown of fats speeds up, which helps clear the blood of ‘bad' cholesterol and triglycerides.
Estonian: Kui need retseptorid on aktiveeritud, siis rasvade lagunemine kiireneb, mis aitab eemaldada verest „halba” kolesterooli ja triglütseriide.
English: The most common side effects with Cholib are raised blood creatinine levels, upper respiratory tract infection (colds), increased blood platelet counts, gastroenteritis (diarrhoea and vomiting) and increased levels of alanine aminotransferase (a liver enzyme).
Estonian: Cholibi kõige sagedamad kõrvalnähud on vere kreatiniinisisalduse suurenemine, ülemiste hingamisteede infektsioonid (külmetused), trombotsüütide arvu suurenemine, gastroenteriit (kõhulahtisus ja oksendamine) ning alaniini aminotransferaasi (maksaensüümi) sisalduse suurenemine.
English: Another study compared Cholib 145/40 mg with simvastatin 40 mg in 450 patients not adequately treated with 40 mg simvastatin alone.
Estonian: Teises uuringus võrreldi Cholibi 145/40 mg annust simvastatiini 40 mg annusega 450 patsiendil, kel ei tekkinud ainult 40 mg simvastatiiniga piisavat ravivastust.
English: Before starting treatment with Cholib, possible causes of the abnormal levels of blood fats should be adequately treated and patients should be placed on a standard fat-lowering diet.
Estonian: Enne ravi alustamist Cholibiga tuleb adekvaatselt ravida vere rasvasisalduse kõrvalekallete põhjuseid ja alustada patsientidel standardset rasvasisaldust vähendavat dieeti.
English: What are the risks associated with Cholib?
Estonian: Mis riskid Cholibiga kaasnevad?
English: In a main study comparing Cholib 145/20 mg with simvastatin 40 mg in 1,050 patients not adequately treated with 20 mg simvastatin alone, triglyceride levels decreased by around 36% with Cholib after 12 weeks compared with 12% with simvastatin.
Estonian: Põhiuuringus, milles võrreldi Cholibi 145/20 mg annust simvastatiini 40 mg annusega 1050 patsiendil, kelle vere rasvasisaldus ei olnud adekvaatselt reguleeritud ainult 20 mg simvastatiiniga, vähenes 12 nädala pärast triglütseriidide sisaldus Cholibi manustamisel umbes 36% ning simvastatiini manustamisel 12%.
English: Cholib can only be obtained with a prescription and is available as tablets (145/20 mg and 145/40 mg).
Estonian: Cholib on retseptiravim ja seda turustatakse 145/20 mg ja 145/40 mg tablettidena.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cholib, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Cholibi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The active substances in Cholib, fenofibrate and simvastatin, work in different ways and their actions have a complementary effect.
Estonian: Cholibi toimeained fenofibraat ja simvastatiin toimivad erineval moel ning nende toimed täiendavad teineteist.
English: It showed that Cholib led to a greater reduction in triglyceride levels (33% versus 7%) and to higher levels of good cholesterol (6% increase versus a 1% decrease).
Estonian: Selle uuringu kohaselt vähendas Cholib triglütseriidide sisaldust rohkem (33% võrreldes 7%-ga) ja suurendas ka „hea” kolesterooli sisaldust rohkem (6% suurenemine võrreldes 1% vähenemisega).
English: In addition, levels of good cholesterol increased by around 7% with Cholib compared with around 2% with simvastatin.
Estonian: Lisaks suurenes „hea” kolesterooli sisaldus Cholibi manustamisel umbes 7% võrreldes umbes 2%-ga simvastatiini manustamisel.
English: Cholib must not be used in people who are hypersensitive (allergic) to peanuts, soya lecithin or any of the ingredients of the medicine.
Estonian: Cholibi ei tohi kasutada inimesed, kes on pähklite, sojaletsitiini või selle ravimi mis tahes koostisaine suhtes ülitundlikud (allergilised).
English: Grapefruit juice should be avoided during Cholib treatment as this is known to alter the amount of simvastatin in the blood.
Estonian: Ravi ajal Cholibiga tuleb vältida greibimahla, sest see muudab teadaolevalt simvastatiini sisaldust veres.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) considered that the combination of fenofibrate and simvastatin has been shown to be effective at improving blood fat levels.
Estonian: Inimravimite komitee leidis, et fenofibraadi ja simvastatiini kombinatsioon on vere rasvasisalduse parandamisel efektiivne.
English: Two further studies compared Cholib with other statins (atorvastatin and pravastatin) and showed Cholib to be more effective than those statins given alone.
Estonian: Cholibi võrreldi teiste statiinidega (atorvastatiin ja pravastatiin) veel kahes uuringus, mis näitasid, et Cholib on efektiivsem kui ainult nende statiinide kasutamine.
English: How is Cholib used?
Estonian: Kuidas Cholibi kasutatakse?
English: As the liver needs cholesterol to produce bile, the reduced blood cholesterol level causes the liver cells to produce receptors that draw cholesterol from the blood, reducing its level even further.
Estonian: Et maks vajab kolesterooli sapi tootmiseks, põhjustab vere vähenenud kolesteroolisisaldus maksarakkudes selliste retseptorite teket, mis eemaldavad verest kolesterooli, vähendades selle sisaldust veelgi.
English: How does Cholib work?
Estonian: Kuidas Cholib toimib?
English: Cholib is to be used in adults at high risk of heart disease whose levels of ‘bad' cholesterol (LDL cholesterol) are already being controlled with the corresponding dose of simvastatin alone.
Estonian: Cholibi kasutatakse südamehaiguse suurema tekkeriskiga patsientidel, kelle „halva” kolesterooli (LDL-kolesterooli) sisaldus on juba reguleeritud vastava simvastatiini annusega.
English: For more information about treatment with Cholib, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Cholibiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For practical information about using Cholib, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Cholibi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Cholib.
Estonian: See on ravimi Cholib Euroopa avaliku hindamisaruande kokkuvõte.
English: For the full list of all side effects reported with Cholib, see the package leaflet.
Estonian: Cholibi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The second active substance, simvastatin, belongs to the group called ‘statins'.
Estonian: Teine toimeaine simvastatiin kuulub statiinide ravimirühma.
English: In all studies the reductions in triglycerides and the increases in good cholesterol were higher with Cholib than with a statin alone.
Estonian: Kõigis uuringutes vähenes triglütseriidide sisaldus ja suurenes „hea” kolesterooli sisaldus Cholibi manustamisel rohkem kui ainult statiiniga.
English: It contains two active substances, fenofibrate and simvastatin, and is used together with a low fat diet and exercise with the aim of reducing patients' levels of triglycerides (a type of fat) and increasing their levels of ‘good' cholesterol (HDL cholesterol).
Estonian: Ravimit kasutatakse koos rasvavaese dieedi ja füüsilise koormusega patsientide triglütseriidide (teatud tüüpi rasva) sisalduse vähendamiseks ning „hea” kolesterooli (HDL-kolesterooli) sisalduse suurendamiseks.
English: What benefits of Cholib have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Cholibi kasulikkus?
English: It reduces total blood cholesterol by blocking the action of HMG-CoA reductase, an enzyme in the liver involved in the production of cholesterol.
Estonian: Simvastatiin vähendab vere üldkolesterooli, blokeerides ensüüm HMG-CoA reduktaasi toimet.
English: This means that it activates a type of receptor called the ‘peroxisome proliferator-activated receptor alpha' (PPARα), which is involved in breaking down fats from diet, especially triglycerides.
Estonian: See tähendab, et ta aktiveerib teatud tüüpi retseptorit, mida nimetatakse peroksisoomproliferaatoraktiveeritava retseptori α-isovormiks.
English: Cholib has been shown to be more effective than statins alone in reducing levels of triglycerides and increasing levels of good cholesterol.
Estonian: On näidatud, et Cholib on triglütseriidide sisalduse vähendamisel ja „hea” kolesterooli sisalduse suurendamisel efektiivsem kui statiinid üksi.
English: Cholib is a medicine for improving blood fat levels.
Estonian: Cholib on vere rasvasisalduse parandamise ravim, mille toimeained on fenofibraat ja simvastatiin.
English: Strength Pharmaceutical Form
Estonian: Vahvuus Lääkemuoto
English: Intravenous use ampoule (glass) 10 ml
Estonian: Intravenoosne Ampull (klaasist) 10 ml
English: 10 ampoules
Estonian: 10 ampulli
English: Intravenous use vial (glass)
Estonian: Intravenoosne Viaal (klaasist) 6 ml
English: Pack size
Estonian: Antoreitti
English: MA (EU) number (Invented) name
Estonian: (Kauppa)nimi
English: Immediate Packaging
Estonian: Sisäpakkaus Määrä (Pitoisuus) Pakkauskoko
English: * Relative potency unit determined by ELISA antigen quantification (in vitro potency test) compared to a reference vaccine.
Estonian: 1,5-3,8 RP* *Suhteline potentsuse ühik, mis on määratud ELISA antigeeni kvantifitseerimisega (in vitro potentsustest) võrreldes referentsvaktsiiniga.
English: --1 Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein
Estonian: --1 Inaktiveeritud rekombinantne kimäärne sigade tsirkoviiruse 1. tüüp, mis sisaldab sigade tsirkoviiruse 2. tüübi valku ORF2 2,3-12,4 RP* Inaktiveeritud Mycoplasma hyopneumoniae, tüvi P-5722-3
English: Strength Pharmaceutical form
Estonian: Tugevus Ravimvorm Loomaliigi d
English: The full EPAR for Topotecan Eagle can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Topotecan Eagle kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The company provided data from the published literature on topotecan.
Estonian: Ettevõte esitas topotekaani kohta avaldatud kirjandusest pärinevad andmed.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Topotecan Eagle on 22 December 2011.
Estonian: Euroopa Komisjon andis Topotecan Eagle müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 22. detsembril 2011.
English: It is also used together with cisplatin (another anticancer medicine) to treat women with cancer of the cervix, when the cancer has come back after radiotherapy, or when the disease is at an advanced stage (stage IVB: the cancer has spread beyond the cervix).
Estonian: Seda kasutatakse ka koos tsisplatiiniga (samuti vähiravim) emakakaelavähi raviks naistel, kellel on vähk pärast kiiritusravi taastunud, ning samuti kaugelearenenud staadiumi korral (IVB staadium: vähk on levinud emakakaelast kaugemale).
English: Topotecan Eagle also has a different (higher) strength from Hycamtin.
Estonian: Topotecan Eagle on teistsuguse (suurema) tugevusega kui Hycamtin.
English: For more information about treatment with Topotecan Eagle, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Topotecan Eaglega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For lung cancer, Topotecan Eagle is given every day for five days with a three-week interval between the start of each course.
Estonian: Kopsuvähi korral manustatakse Topotecan Eaglet iga päev 5 päeva jooksul, jättes ravikuuride alguse vahele 3nädalase intervalli.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Topotecan Eagle.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Other information about Topotecan Eagle
Estonian: Muu teave Topotecan Eagle kohta
English: The Committee recommended that Topotecan Eagle be given marketing authorisation.
Estonian: Komitee soovitas anda Topotecan Eagle müügiloa.
English: Because Topotecan Eagle is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Topotecan Eagle on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: No additional studies in patients were needed as Topotecan Eagle is given by infusion and contains the same active substance as the reference medicine, Hycamtin.
Estonian: Patsientide lisauuringuid ei olnud vaja, sest Topotecan Eagle on infusioonina manustatav ravim, mis sisaldab sama toimeainet kui võrdlusravim Hycamtin.
English: When used with cisplatin in cervical cancer, Topotecan Eagle is given as an infusion on days 1, 2 and 3 (with cisplatin given on day 1).
Estonian: Koos tsisplatiiniga emakakaelavähi raviks kasutamisel manustatakse Topotecan Eaglet infusioonina 1., 2. ja 3. päeval (manustades tsisplatiini 1. päeval).
English: EPAR summary for the public topotecan
Estonian: Kokkuvõte üldsusele topotekaan
English: Treatment with Topotecan Eagle should only be given under the supervision of a doctor experienced in the use of chemotherapy.
Estonian: Ravi Topotecan Eaglega peab toimuma üksnes keemiaravi kasutamises kogenud arsti järelevalve all.
English: The CHMP concluded that, in accordance with EU requirements, Topotecan Eagle has been shown to have comparable quality and to be bioequivalent to Hycamtin.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Topotecan Eagle võrdväärne kvaliteet ja bioekvivalentsus ravimiga Hycamtin.
English: Topotecan Eagle also affects non-cancer cells, which causes side effects.
Estonian: Topotecan Eagle mõjutab ka muid rakke peale vähirakkude ning see põhjustab kõrvalnähte.
English: This is a summary of the European public assessment report (EPAR) for Topotecan Eagle.
Estonian: See on ravimi Topotecan Eagle Euroopa avaliku hindamisaruande kokkuvõte.
English: For full details, see the Summary of Product Characteristics, also part of the EPAR.
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
English: The dose of Topotecan Eagle to be used depends on the type of cancer that it is being used to treat and the patient's weight and height.
Estonian: Topotecan Eagle annus sõltub ravitavast vähiliigist ning patsiendi kaalust ja pikkusest.
English: Therefore, the CHMP's view was that, as for Hycamtin, the benefit outweighs the identified risk.
Estonian: Seetõttu leidis inimravimite komitee, et nagu ka Hycamtini korral, ületab Topotecan Eagle kasulikkus sellega kaasnevad riskid.
English: While the reference medicine, Hycamtin, is available as a powder to be made up into a concentrate, Topotecan Eagle is available as a ready-made concentrate.
Estonian: Kui võrdlusravim Hycamtini turustatakse pulbrina, millest valmistatakse kontsentraat, siis Topotecan Eaglet turustatakse valmiskontsentraadina.
English: Topotecan Eagle is a medicine that contains the active substance topotecan.
Estonian: Topotecan Eagle on ravim, mis sisaldab toimeainena topotekaani.